news

CUPERTINO, Calif., June 25 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has filed a Special 510(k) pre-market notification with the FDA for its next generation ear delivery catheter. Like its predecessor IntraEAR(R) catheters, the Microdose Cath(TM) is intended for the site-directed delivery of fluids to the round window area of the middle […]

CUPERTINO, Calif., May 24 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX – news) today announced that it has completed construction of a commercial manufacturing facility that is expected to meet DURECT’s production needs for Phase III clinical batches, FDA registration batches and commercial launch of DUROS sufentanil. The facility is designed to use advanced procedures to

CUPERTINO, Calif., May 11 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that the company has completed the clinical portion of its Phase II clinical trial for the company’s lead product, DUROS sufentanil. The last patient visit was completed and data analysis and report writing are underway. Over 50 patients at 9 clinical centers completed

CUPERTINO, Calif., April 30 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2001. The company’s net loss attributable to common stockholders for the three months ended March 31, 2001 was $4.9 million or 11 cents per share, compared to $4.7 million, or 71 cents per share,

CUPERTINO, Calif., April 30 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has acquired Southern BioSystems, Inc. (“SBS”), a privately held company located in Birmingham, Alabama. SBS develops, manufactures and sells biodegradable polymer and non-polymer drug delivery systems. SBS also provides bulk supply of biodegradable polymer for seven FDA approved products sold by

CUPERTINO, Calif., April 24 /PRNewswire Interactive News Release/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, April 30th, 2001 at 4:30 p.m. EDT with Jim Brown, President and Chief Executive

CUPERTINO, Calif., April 3 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Dennis M. Fisher, M.D. has been promoted to the position of Vice President for Medical Affairs. Dr. Fisher joined DURECT in June 2000 as Medical Director. Dr. Fisher, previously Professor of Anesthesia and Pediatrics at the University of California San Francisco, has

CUPERTINO, Calif., March 27 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has a long-term supply agreement with Mallinckrodt, a global manufacturer and marketer of specialty medical products. Mallinckrodt will supply DURECT’s clinical and commercial requirements for sufentanil, a potent opioid analgesic and critical component of the company’s lead product DUROS sufentanil, for

CUPERTINO, Calif., March 9 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that the company has completed patient enrollment of its Phase II clinical trial for the company’s lead product, DUROS sufentanil. Over 50 patients at 10 clinical centers were enrolled in the trial more than one-quarter ahead of schedule. DURECT anticipates meeting with the

CUPERTINO, Calif., March 1 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today the appointment of Armand P. Neukermans Ph.D. to its Board of Directors. Dr. Neukermans is currently Chief Technical Officer of the Xros division at Nortel Networks. Dr. Neukermans has over 30 years of experience in the field of electrical and mechanical engineering. Since